amphotericin b


Gilead Sciences


DCH Auriga - Healthcare
Four Star
Concise Prescribing Info
Liposomal amphotericin B
Systemic mycotic infections due to susceptible organisms. Fever of unknown origin in neutropenic patients. As primary therapy of visceral leishmaniasis in immunocompetent adult & childn patients & in immunocompromised patients.
Dosage/Direction for Use
Dosage must be adjusted to the specific requirements of each patient. Recommended IV infusion: 0.2-2 mg/mL. Adult Systemic mycotic infections Daily dose of 1 mg/kg; increase stepwise to 3 mg/kg as required. Fever of unknown origin Initiate at 1 mg/kg/day; raise to 3 mg/kg/day if indicated. Visceral leishmaniasis 1-1.5 mg/kg/day for 21 days or alternatively 3 mg/kg/day for 10 days. Paed patient 1 mth-18 yr Calculate dosage on the same per kg body wt basis as for adults.
Hypersensitivity to amphotericin B; peanut or soya.
Special Precautions
Anaphylaxis & anaphylactoid reactions; other severe infusion-related reactions; acute pulmonary toxicity during or shortly after leukocyte transfusions; renal adverse reactions. Perform regular laboratory evaluation of serum electrolytes (particularly K & Mg), renal, hepatic & haematopoietic function. Contains approx 900 mg sucrose in each vial; caution in DM patients. Avoid administration during haemodialysis or filtration procedures. Patients w/ rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. Some adverse reactions may impair ability to drive or operate machinery. Pregnancy & lactation. Infant <1 mth.
Adverse Reactions
Hypokalaemia; nausea, vomiting; rigors, pyrexia. Hyponatraemia, hypocalcaemia, hypomagnesaemia, hyperglycaemia; headache; tachycardia; hypotension, vasodilatation, flushing; dyspnoea; diarrhoea, abdominal pain; abnormal liver function tests, hyperbilirubinaemia, increased alkaline phosphatase; rash; back pain; increased creatinine & blood urea; chest pain.
Drug Interactions
Enhanced potential for drug-induced renal toxicity w/ nephrotoxic agents (eg, ciclosporin, aminoglycosides & pentamidine). Potentiated hypokalaemia w/ corticosteroids, ACTH & diuretics (loop & thiazide). Potentiated digitalis toxicity. Enhanced curariform effect of skeletal muscle relaxants (eg, tubocurarine). Increased flucytosine toxicity. Enhanced potential for renal toxicity, bronchospasm & hypotension w/ antineoplastic agents. Risk of acute pulmonary toxicity when given during or shortly after leukocyte transfusions.
MIMS Class
ATC Classification
J02AA01 - amphotericin B ; Belongs to the class of antibiotics. Used in the systemic treatment of mycotic infections.
AmBisome powd for conc for dispersion for infusion 50 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in